

ANGIODYNAMICS INC
Form 10-Q/A
April 11, 2006
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A
(Amendment No. 1)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended February 25, 2006

OR

.. TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 1-50761

AngioDynamics, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

11-3146460
(I.R.S. Employer
Identification No.)

Edgar Filing: ANGIODYNAMICS INC - Form 10-Q/A

603 Queensbury Ave., Queensbury, New York
(Address of principal executive offices)

(518) 798-1215

12804
(Zip Code)

Registrant's telephone number, including area code

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. Check one:

Large accelerated filer Accelerated filer Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of March 22, 2006, there were 12,504,839 shares of the issuer's common stock outstanding.

Table of Contents**Explanatory Note**

This amendment on Form 10-Q/A to the quarterly report on Form 10-Q for the quarterly period ended February 25, 2006 of AngioDynamics, Inc. is being filed to correct exhibits 32.1 and 32.2 thereto. Except for the corrections to exhibits 32.1 and 32.2, no other information included in the original report on Form 10-Q is amended by this amendment on Form 10-Q/A.

AngioDynamics, Inc. and Subsidiary**INDEX**

	Page
<u>Part I: Financial Information</u>	
Item 1.	
<u>Financial Statements</u>	
<u>Consolidated Balance Sheets - February 25, 2006 (unaudited) and May 28, 2005</u>	3 - 4
<u>Consolidated Statements of Income - Thirteen and thirty-nine weeks ended February 25, 2006 and February 26, 2005 (unaudited)</u>	5
<u>Consolidated Statement of Stockholders' Equity and Comprehensive Income - Thirty-nine weeks ended February 25, 2006 (unaudited)</u>	6
<u>Consolidated Statements of Cash Flows - Thirty-nine weeks ended February 25, 2006 and February 26, 2005 (unaudited)</u>	7 - 8
<u>Notes to Consolidated Financial Statements</u>	9 - 21
Item 2.	22 - 29
<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	
Item 3.	29
<u>Quantitative and Qualitative Disclosures About Market Risk</u>	
Item 4.	30
<u>Controls and Procedures</u>	
<u>Part II: Other Information</u>	
Item 1.	31 - 32
<u>Legal Proceedings</u>	
Item 1A.	32
<u>Risk Factors</u>	
Item 2.	32
<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	
Item 3.	32
<u>Defaults Upon Senior Securities</u>	
Item 4.	32
<u>Submission of Matters to a Vote of Security Holders</u>	
Item 5.	32
<u>Other Information</u>	
Item 6.	33
<u>Exhibits</u>	

Table of Contents

AngioDynamics, Inc. and Subsidiary

CONSOLIDATED BALANCE SHEETS

(in thousands)

	February 25,	May 28,
	2006 (unaudited)	2005 (audited)
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	\$ 13,356	\$ 14,498
Marketable securities, at fair value	15,551	12,601
Accounts receivable - trade, net of allowance for doubtful accounts of \$287 and \$203, respectively	12,182	9,929
Inventories	13,137	10,264
Deferred income taxes	707	736
Due from former parent		85
Prepaid expenses and other	1,164	1,594
Total current assets	56,097	49,707
PROPERTY, PLANT AND EQUIPMENT - AT COST, less accumulated depreciation and amortization	10,355	8,528
DEFERRED INCOME TAXES	586	501
INTANGIBLE ASSETS, less accumulated amortization of \$1,173 and \$1,036, respectively	3,095	839
OTHER ASSETS	94	97
TOTAL ASSETS	\$ 70,227	\$ 59,672

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

AngioDynamics, Inc. and Subsidiary

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

	February 25, 2006 (unaudited)	May 28, 2005 (audited)
LIABILITIES AND STOCKHOLDERS EQUITY		
CURRENT LIABILITIES		
Accounts payable	\$ 4,903	\$ 3,971
Accrued liabilities	4,514	3,491
Income taxes payable	496	
Current portion of long-term debt	180	165
Total current liabilities	10,093	7,627
LONG-TERM DEBT, net of current portion	2,800	2,935
Total liabilities	12,893	10,562
COMMITMENTS AND CONTINGENCIES		
STOCKHOLDERS EQUITY		
Preferred stock, par value \$.01 per share - 5,000,000 shares authorized; no shares issued and outstanding		
Common stock, par value \$.01 per share - 45,000,000 shares authorized; issued and outstanding 12,434,212 shares at February 25, 2006 and 12,051,632 shares at May 28, 2005	124	121
Additional paid-in capital	56,257	52,878
Retained earnings (accumulated deficit)	1,108	(3,720)
Accumulated other comprehensive loss	(155)	(169)
Total stockholders equity	57,334	49,110
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	\$ 70,227	\$ 59,672

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

AngioDynamics, Inc. and Subsidiary

CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(in thousands, except per share data)

	Thirteen weeks ended		Thirty-nine weeks ended February 26,	
	February 25, 2006	February 26, 2005	February 25, 2006	2005
Net sales	\$ 19,785	\$ 15,450	\$ 54,859	\$ 42,957
Cost of goods sold	8,237	6,885	22,945	19,336
Gross profit	11,548	8,565	31,914	23,621
Operating expenses				
Selling and marketing	5,294	4,147	15,021	11,382
General and administrative	1,919	1,244	5,181	3,753
Research and development	1,446	1,026	4,510	3,276
Total operating expenses	8,659	6,417	24,712	18,411
Operating profit	2,889	2,148	7,202	5,210
Other income (expenses)				
Interest income	219	77	549	190
Impairment loss on investment		(300)		(300)
Interest expense	(33)	(38)	(103)	(113)
Other income	38	16	149	16
Income before income tax provision	3,113	1,903	7,797	5,003
Income tax provision	1,233	818	2,969	2,121
NET INCOME	\$ 1,880	\$ 1,085	\$ 4,828	\$ 2,882
Earnings per common share				
Basic	\$.15	\$.09	\$.39	\$.25
Diluted	\$.14	\$.09	\$.37	\$.24

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

AngioDynamics, Inc. and Subsidiary

CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY AND COMPREHENSIVE INCOME

Thirty-nine weeks ended February 25, 2006

(unaudited)

(in thousands, except share data)

	Common stock		Additional paid-in capital	Retained earnings (Accumulated deficit)	Accumulated other comprehensive loss	Total	Comprehensive income
	Shares	Amount					
Balance at May 28, 2005	12,051,632	\$ 121	\$ 52,878	\$ (3,720)	\$ (169)	\$ 49,110	
Net income				4,828		4,828	\$ 4,828
Exercise of stock options	364,746	3	1,704			1,707	
Tax benefit on exercise of stock options			1,339			1,339	
Purchases of common stock under Employee Stock Purchase Plan (the ESPP)	17,834		271			271	
Compensation related to stock option plans			65			65	
Unrealized loss on marketable securities, net of tax of \$37					(62)	(62)	(62)
Unrealized gain on interest rate swap, net of tax of \$44					76	76	76
Comprehensive income							\$ 4,842
Balance at February 25, 2006	12,434,212	\$ 124	\$ 56,257	\$ 1,108	\$ (155)	\$ 57,334	

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

AngioDynamics, Inc. and Subsidiary

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

	Thirty-nine weeks ended	
	February 25, 2006	February 26, 2005
Cash flows from operating activities:		
Net income	\$ 4,828	\$ 2,882
Adjustments to reconcile net income to net cash provided by operating activities		
Depreciation and amortization	756	563
Tax benefit on exercise of stock options	1,339	910
Impairment loss on investment		300
Gain on sale of marketable securities	(149)	(16)
Deferred income tax provision	(64)	
Provision for doubtful accounts	85	15
Compensation related to stock option plans	321	52
Changes in operating assets and liabilities		
Accounts receivable	(2,338)	(421)
Inventories	(2,873)	(844)
Due from/to former parent	85	(596)
Prepaid expenses and other	430	(338)
Accounts payable and accrued liabilities	1,820	589
Income taxes payable	496	(99)
Net cash provided by operating activities	4,736	2,997
Cash flows from investing activities:		
Additions to property, plant and equipment	(2,443)	(894)
Acquisition of distribution rights	(2,393)	
Decrease in restricted cash		101
Purchases of marketable securities	(18,416)	(11,316)
Proceeds from sales of marketable securities	15,516	2,447
Net cash used in investing activities	(7,736)	(9,662)
Cash flows from financing activities:		
Repayment of long-term debt	(120)	(115)
Payment of note payable - former parent		(3,000)
Proceeds from stock subscription receivable		19,949
Proceeds from issuance of common stock		2,992
Proceeds from issuance of common stock under the ESPP	271	65
Proceeds from the exercise of stock options	1,707	1,380
Payments of costs relating to initial public offering		(949)
Net cash provided by financing activities	1,858	20,322
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(1,142)	13,657

Edgar Filing: ANGIODYNAMICS INC - Form 10-Q/A

Cash and cash equivalents			
Beginning of period		14,498	1,747
End of period		\$ 13,356	\$ 15,404

-7-

Table of Contents

AngioDynamics, Inc. and Subsidiary

CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)

(unaudited)

(in thousands)

	Thirty-nine weeks ended	
	February 25,	February 26,
	2006	2005
Supplemental disclosures of cash flow information:		
Cash paid during the period for:		
Interest	\$ 104	\$ 113
Income taxes	\$ 938	\$ 510

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

AngioDynamics, Inc. and Subsidiary

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

February 25, 2006 and February 26, 2005

(unaudited)

NOTE A - CONSOLIDATED FINANCIAL STATEMENTS

The consolidated balance sheet as of February 25, 2006, the consolidated statement of stockholders' equity and comprehensive income for the thirty-nine weeks ended February 25, 2006, and the consolidated statements of income and cash flows for the periods ended February 25, 2006 and February 26, 2005, have been prepared by the Company without audit. The consolidated balance sheet as of May 28, 2005, was derived from audited consolidated financial statements. In the opinion of management, all adjustments (which include only normally recurring adjustments) necessary to state fairly the financial position, changes in stockholders' equity and comprehensive income, results of operations and cash flows as of February 25, 2006 (and for all periods presented) have been made.

Certain information and footnote disclosures, normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted. It is suggested that these unaudited interim consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Annual Report on Form 10-K for the fiscal year ended May 28, 2005, filed by the Company on August 26, 2005. The results of operations for the periods ended February 25, 2006 and February 26, 2005 are not necessarily indicative of the operating results for the respective full fiscal years.

The unaudited interim consolidated financial statements include the accounts of AngioDynamics, Inc. and its wholly-owned subsidiary, Leocor, Inc. (Leocor) (collectively, the Company). All significant intercompany balances and transactions have been eliminated. The Company's operations are classified in one segment, peripheral vascular disease, as management of the Company's products and services follows principally the same marketing, production, and technology strategies.

NOTE B - STOCK-BASED COMPENSATION

As of February 25, 2006, the Company had two stock-based compensation plans, exclusive of the stock option plans related to the distribution by E-Z-EM, Inc. (E-Z-EM or the Former Parent) of all of its shares of the Company's common stock to the E-Z-EM stockholders in October 2004 (the Spin-off)(see Note L). The Company accounts for these plans under the recognition and measurement principles of APB Opinion No. 25, Accounting for Stock Issued to Employees , SFAS No. 123, Accounting for Stock-based Compensation for non-employees, and related interpretations. Accordingly, no compensation expense has been recognized under these plans concerning options granted to key employees and to members of the Board of Directors, as all such options granted had an exercise price equal to or greater than the market value of the underlying common stock on the date of grant. During the thirteen weeks ended February 25, 2006 and February 26, 2005, compensation expense of \$21,000 and \$19,000, respectively, was recognized under these plans for options granted to consultants. During the thirty-nine weeks ended February 25, 2006 and February 26, 2005, compensation expense of \$65,000 and \$52,000, respectively, was recognized under these plans for options granted to consultants. During

Table of Contents

AngioDynamics, Inc. and Subsidiary

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

February 25, 2006 and February 26, 2005

(unaudited)

NOTE B - STOCK-BASED COMPENSATION (continued)

the thirteen and thirty-nine weeks ended February 25, 2006, compensation expense of \$104,000 and \$256,000, respectively, was recognized under these plans for restricted stock unit and performance share awards granted to employees.

Performance share awards are accounted for under the provisions of APB No. 25 for variable awards.

If the Company had elected to recognize compensation expense based upon the fair value at the grant date for options and awards granted under these plans to employees and to members of the Board of Directors, consistent with the methodology prescribed by SFAS No. 123, the Company's pro forma net income and earnings per common share would be as follows:

	Thirteen weeks ended		Thirty-nine weeks ended	
	February 25, 2006	February 26, 2005	February 25, 2006	February 26, 2005
	(in thousands)			
Net income				
As reported	\$ 1,880	\$ 1,085	\$ 4,828	\$ 2,882
Add total stock-based compensation recorded under intrinsic value based method for all awards, net of tax effects	83	13	212	34
Deduct total stock-based compensation under fair value based method for all awards, net of tax effects	(421)	(404)	(1,019)	(1,108)
Pro forma net income	\$ 1,542	\$ 694	\$ 4,021	\$ 1,808
Earnings per common share				
Basic - as reported	\$.15	\$.09	\$.39	\$.25
Basic - pro forma	.13	.06	.33	.16
Diluted - as reported	\$.14	\$.09	\$.37	\$.24
Diluted - pro forma	.12	.06	.31	.15

-10-

Table of Contents

AngioDynamics, Inc. and Subsidiary

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

February 25, 2006 and February 26, 2005

(unaudited)

NOTE C - EARNINGS PER COMMON SHARE

Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share are based on the weighted average number of common and potential common shares outstanding. The calculation takes into account the shares that may be issued upon exercise of stock options and restricted stock unit awards, reduced by the shares that may be repurchased with the funds received from the exercise, based on the average price during the period.

The following table sets forth the reconciliation of the weighted-average number of common shares:

	Thirteen weeks ended		Thirty-nine weeks ended	
	February	February	February	February
	25,	26,	25,	26,
	2006	2005	2006	2005
Basic	12,367,348	11,606,055	12,253,254	11,498,425
Effect of dilutive securities	623,302	875,794	655,546	694,093
Diluted	12,990,650	12,481,849	12,908,800	12,192,518

NOTE D - ACCUMULATED OTHER COMPREHENSIVE LOSS

The components of accumulated other comprehensive loss, net of related tax, are as follows:

	February 25,	May 28,
	2006	2005
	(in thousands)	
Fair value on interest rate swap	\$ (104)	\$ (180)
Unrealized holding (loss) gain on marketable securities	(51)	11
Accumulated other comprehensive loss	\$ (155)	\$ (169)

Table of Contents

AngioDynamics, Inc. and Subsidiary

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

February 25, 2006 and February 26, 2005

(unaudited)

NOTE E - MARKETABLE SECURITIES

Marketable securities as of February 25, 2006, consist of the following:

	Amortized cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair value
	(in thousands)			
Marketable securities				
U.S. government agency obligations	\$ 7,508	\$ 10	\$ (33)	\$ 7,485
Corporate bond securities	8,127		(61)	8,066
	\$ 15,635	\$ 10	\$ (94)	\$ 15,551

Marketable securities as of May 28, 2005 consist of the following:

	Amortized cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair value
	(in thousands)			
Marketable securities				
U.S. government agency obligations	\$ 7,642	\$ 30	\$ (45)	\$ 7,627
Corporate bond securities	4,944	30		4,974
	\$ 12,586	\$ 60	\$ (45)	\$ 12,601

As of February 25, 2006, the Company held securities with a fair value of \$12,382,000, that had unrealized losses totaling \$94,000. As of May 28, 2005, the Company held securities with a fair value of \$4,456,000, that had unrealized losses totaling \$45,000.

The amortized cost and fair value of marketable securities as of February 25, 2006, by contractual maturity, are shown below. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

	Amortized Cost	Fair Value
	(in thousands)	
Due in one year or less	\$ 14,616	\$ 14,544
Due after one through five years	1,019	1,007
	\$ 15,635	\$ 15,551

Table of Contents

AngioDynamics, Inc. and Subsidiary

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

February 25, 2006 and February 26, 2005

(unaudited)

NOTE F - INVENTORIES

Inventories consist of the following:

	February 25,	May 28,
	2006	2005
	(in thousands)	
Finished goods	\$ 7,373	\$ 6,014
Work in process	1,485	1,532
Raw materials	4,279	2,718
	\$ 13,137	\$ 10,264

Allowances for excess and obsolete inventory were \$1,184,000 and \$779,000 at February 25, 2006 and May 28, 2005, respectively.

NOTE G - DISTRIBUTION AGREEMENT

In June 2004, the Company signed a Distribution Agreement (the Agreement) granting to the Company worldwide exclusive rights to market, sell, and distribute products for use in image-guided procedures. The Agreement is effective for an initial term of ten years and will automatically renew for an additional five-year period if certain minimum purchase requirements are met. In consideration for these rights, the Company will pay up to \$1,000,000 in five installments, each contingent upon the achievement of specified product development and approval milestone events, as defined. During the thirty-nine weeks ended February 25, 2006, the Company made an installment payment of \$200,000, which has been recorded as a component of research and development expenses.

Table of Contents

AngioDynamics, Inc. and Subsidiary

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

February 25, 2006 and February 26, 2005

(unaudited)

NOTE H - SUPPLY AND DISTRIBUTION RIGHTS AGREEMENT

On October 17, 2005, the Company entered into a Supply and Distribution Rights Agreement (the Agreement) with Bioniche Pharma Group Limited (Bioniche).

Under the Agreement, the Company was appointed the exclusive distributor in the Field (as defined below) in the United States and any other areas as may be agreed to by the parties (the Territory) of Bioniche's sodium tetradecyl sulfate product in concentrations of 1% and 3%, and any concentration subsequently approved by the U.S. Food and Drug Administration (the FDA), brand name Sotradecol, and any improvements thereto, during the term of the Agreement, together with packaging, labeling and accessories (the Product).

The distribution rights cover sales to general surgeons, vascular surgeons, general/vascular surgeons, interventional radiologists, cardiovascular surgeons, cardiothoracic surgeons and cardiologists for the treatment of varicose veins or other vascular indications as may be approved by the FDA (the Field). Sotradecol is used in sclerotherapy, a non-surgical procedure to remove varicose veins.

The Agreement also provides the Company with a right of first negotiation for any additional products developed by Bioniche or its affiliates for use in the Field in the Territory. The Company has agreed not to distribute, market or sell in the Field in the Territory during the term of the Agreement any other sclerosing agent approved by the FDA for use in the treatment of varicose veins or other vascular indications in the Territory.

The initial term of the Agreement is seven years, with automatic successive three-year renewal terms unless terminated by either party on 120 days' written notice. Under the Agreement, the Company is required to pay Bioniche a non-refundable fee of \$2.3 million, consisting of \$1.5 million payable 30 days after the date of the Agreement and \$800,000 payable at the end of the Company's first fiscal quarter following the first commercial sale of Product.

To maintain its exclusive distribution rights, the Company must purchase minimum quantities of Product in each year of the Agreement. If the Company fails to do so, Bioniche's sole remedy is to convert the relationship to a non-exclusive distributorship. If a pharmaceutical product containing sodium tetradecyl sulfate or polidocanol as the active ingredient which is approved by the FDA for use in the treatment of varicose veins or other vascular indications in the Territory, other than the Product, is sold in the Field in the Territory by an unaffiliated third party during the term of the Agreement, the annual minimum purchase requirements will automatically be reduced by 50% for the remainder of the Agreement and any renewal term.

Bioniche has agreed to indemnify the Company against, among other things, any injury, illness or death of any person due to the composition or manufacture of the Product. The Company has agreed to indemnify Bioniche against, among other things, any claims based on or attributable to any unauthorized

Table of Contents

AngioDynamics, Inc. and Subsidiary

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

February 25, 2006 and February 26, 2005

(unaudited)

NOTE H - SUPPLY AND DISTRIBUTION RIGHTS AGREEMENT (continued)

modification or alteration of the Product made by the Company or the combination by the Company of the Product with any medical device. As of February 25, 2006, there were no claims made against either party, and the Company is unable to determine any potential exposure it may have under the indemnification provision.

During the thirteen weeks and thirty-nine weeks ended February 25, 2006, the Company made installment payments of \$800,000 and \$2,300,000, respectively. Including legal costs to execute the Agreement of \$93,000, a total of \$2,393,000 has been recorded on the balance sheet under Intangible Assets as of February 25, 2006. The non-refundable fees and associated costs to execute the Agreement are being amortized over the initial seven-year term of the Agreement.

NOTE I - ACCRUED LIABILITIES

Accrued liabilities consist of the following:

	February 25, 2006	May 28, 2005
	(in thousands)	
Payroll and related expenses	\$ 3,126	\$ 2,537
Sales and franchise taxes	808	75
Fair value of interest rate swap	166	286
Other	414	593
	\$ 4,514	\$ 3,491

NOTE J - INCOME TAXES

The Company's effective income tax rate for the thirteen and thirty-nine weeks ended February 25, 2006 was 39.6% and 38.0%, respectively, compared to 43.0% and 42.4% for the thirteen and thirty-nine weeks ended February 26, 2005. The decrease is primarily attributable to a non-deductible capital loss incurred during the prior period, offset by additional income taxes incurred in the current period under the Company's tax sharing arrangement with the Former Parent in conjunction with the Former Parent's filing of the consolidated fiscal 2005 Federal income tax return, which included taxable income of the Company prior to the Spin-off.

Table of Contents

AngioDynamics, Inc. and Subsidiary

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

February 25, 2006 and February 26, 2005

(unaudited)

NOTE K - RELATED PARTY TRANSACTIONS

Certain identifiable, allocable costs incurred by the Former Parent on behalf of the Company for commissions, foreign selling expenses and administrative expenses were proportionately charged to the Company through December 31, 2004, under the Master Separation and Distribution Agreement with the Former Parent.

In addition to the allocations, the Former Parent provided insurance coverage to the Company through October 30, 2004. The amount payable by the Company for such coverage was the actual cost of such insurance as allocated by the insurance carrier providing such coverage, and if such allocation was not provided by the insurance carrier, the amount payable by the Company was determined by the Former Parent based upon the respective total revenues of the Former Parent and the Company and such other factors as the Former Parent reasonably determined to be appropriate.

For the thirteen and thirty-nine weeks ended February 25, 2006, the Company did not incur any charges from the Former Parent for insurance or corporate services. For the thirteen weeks ended February 26, 2005, the Company incurred charges of \$26,000 for corporate services. For the thirty-nine weeks ended February 26, 2005, the Company incurred charges of \$211,000 and \$148,000, from the Former Parent for insurance and corporate services, respectively.

NOTE L - COMMON STOCK

Stock Option Plans

During the thirteen and thirty-nine weeks ended February 25, 2006, options for a total of 32,150 and 337,950 shares of common stock, respectively, were granted to employees and directors under the 2004 Stock and Incentive Award Plan (the 2004 Plan). During the thirty-nine weeks ended February 25, 2006, options for a total of 1,000 shares of common stock were granted to consultants under the 1997 Stock Option Plan (the 1997 Plan). All options were granted at exercise prices equal to the quoted market price of the Company's common stock at the date of the grants. Options under these grants vest 25% per year over four years for employees and new directors, 33 1/3% per year over three years for existing directors, and 100% after one year for consultants. All options expire on the tenth anniversary of the grant date.

Options for a total of 99,187 and 7,270 shares of common stock were exercised under the 1997 Plan and 2004 Plan, respectively, during the thirteen weeks ended February 25, 2006, at prices ranging from \$4.35 to \$13.18 per share. Options for a total of 242,137 and 8,731 shares of common stock were exercised under the 1997 Plan and 2004 Plan, respectively, during the thirty-nine weeks ended February 25, 2006, at prices ranging from \$4.35 to \$13.18 per share.

Table of Contents

AngioDynamics, Inc. and Subsidiary

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

February 25, 2006 and February 26, 2005

(unaudited)

NOTE L - COMMON STOCK (continued)

During the thirteen weeks ended February 25, 2006, options for a total of 1,523 and 2,787 shares of common stock were forfeited under the 1997 Plan and 2004 Plan, respectively, at prices ranging from \$6.52 to \$20.70 per share. During the thirty-nine weeks ended February 25, 2006, options for a total of 3,859 and 13,437 shares of common stock were forfeited under the 1997 Plan and 2004 Plan, respectively, at prices ranging from \$4.35 to \$24.21 per share.

As of February 25, 2006, options to acquire 655,530 and 61,153 shares of common stock were exercisable under the 1997 Plan and 2004 Plan, respectively.

In connection with the Spin-off, as of October 29, 2004, all outstanding E-Z-EM options (E-Z-EM Pre-spin Options) were adjusted and Company options (the Mirror Options) were issued to E-Z-EM option holders. The adjusted E-Z-EM Pre-spin Options and the Mirror Options are collectively referred to herein as the Replacement Options .

The exercise price and the number of shares subject to each Replacement Option was established pursuant to a formula designed to ensure that: (1) the aggregate intrinsic value (i.e., the difference between the exercise price of the option and the market price of the common stock underlying the option) of the Replacement Option did not exceed the aggregate intrinsic value immediately prior to the spin-off of the outstanding E-Z-EM Pre-spin Option replaced by such Replacement Option and (2) the ratio of the exercise price of each option to the market value of the underlying stock immediately before and after the spin-off was preserved.

Substantially all of the other terms and conditions of each Replacement Option, including the time or times when, and the manner in which, each option is exercisable, the permitted method of exercise, settlement and payment, the rules that apply in the event of the termination of employment of the employee, the events, if any, that may give rise to an employee's right to accelerate the vesting or the time or exercise thereof and the vesting provisions, are the same as those of the replaced E-Z-EM Pre-spin Option, except for the duration of the exercise periods of the Mirror Options, all of which will expire no later than May 2008. In addition, option holders who are employed by one company are permitted to exercise, and are subject to all of the terms and provisions of, options to acquire shares in the other company as if such holder was an employee of such other company.

As a result of the spin-off, on October 29, 2004, Mirror Options for 421,926 shares of the Company's common stock, with a weighted average exercise price of \$4.22, were issued to E-Z-EM officers, directors, employees and consultants.

Mirror Options for a total of 36,538 and 113,878 shares of common stock were exercised during the thirteen and thirty-nine weeks ended February 25, 2006, respectively, at prices ranging from \$2.56 to \$9.80 per share. During the thirteen and thirty-nine weeks ended February 25, 2006, Mirror Options for a total of 4,270 and 10,172 shares of common stock, respectively, were

Table of Contents

AngioDynamics, Inc. and Subsidiary

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

February 25, 2006 and February 26, 2005

(unaudited)

NOTE L - COMMON STOCK (continued)

forfeited at prices ranging from \$2.88 to \$4.50 per share. Mirror Options to acquire 80,551 shares of common stock were exercisable as of February 25, 2006. Options for 50,907 shares expire on or before November 23, 2006, and the Company anticipates option holders will exercise these options before such date.

Employee Stock Purchase Plan

In July 2004, the Company adopted the AngioDynamics, Inc. Employee Stock Purchase Plan (the "Stock Purchase Plan"), which was approved by stockholders on October 18, 2004. The Stock Purchase Plan provides a means by which employees of the Company (the "participants") may be given an opportunity to purchase common stock of the Company through payroll deductions. The maximum number of shares to be offered under the Stock Purchase Plan will be 200,000 shares of the Company's common stock, subject to any increase authorized by the board of directors. Shares will be offered through two overlapping offering periods, each with a duration of approximately 12 months, commencing on the first business day on or after December 1st and June 1st of each year, and each consisting of a series of successive three-month purchase periods. A participant may not participate in more than one offering period at a time. An employee is eligible to participate in an offering period if, on the first day of an offering period, he or she has been employed in a full-time capacity for at least six months, with a customary working schedule of 20 or more hours per week and more than five months in a calendar year. Employees who own stock possessing 5% or more of the total combined voting power or value of all classes of the Company's stock are not eligible to participate in the Stock Purchase Plan. The purchase price of the shares of common stock acquired on each purchase date will be the lower of (i) 85% of the fair market value of a share of common stock on the first day of the offering period or (ii) 85% of the fair market value of a share of common stock on the last day of the purchase period, subject to adjustments made by the board of directors. The Stock Purchase Plan is intended to qualify as an "employee stock purchase plan" within the meaning of Section 423 of the Internal Revenue Code. For the thirteen and thirty-nine weeks ended February 25, 2006, 5,473 and 17,834 shares, respectively, were issued at an average price of \$16.96 and \$15.20 per share, respectively, under the Stock Purchase Plan.

Performance Share and Restricted Stock Unit Awards

On May 11, 2005, the compensation committee of the Company's board of directors approved grants of 33,750 performance share awards and 33,750 restricted stock unit awards under the 2004 Plan to the Company's executive officers, effective June 1, 2005. The performance criteria established by the compensation committee for earning the performance share awards is the achievement of certain earnings per share ("EPS") goals and revenue goals by the Company for each of the 2006 through 2009 fiscal years. Shares not earned in a fiscal year may be earned in the following fiscal year if the EPS or revenue goals in such following year are exceeded by an amount at least equal to the shortfall for the applicable goal for the preceding year. The performance share awards are subject to additional conditions, including the recipient's continued employment with the Company. The restricted stock unit awards vest in full upon the recipient's continued employment with the

Table of Contents

AngioDynamics, Inc. and Subsidiary

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

February 25, 2006 and February 26, 2005

(unaudited)

NOTE L - COMMON STOCK (continued)

Company through the end of the Company's fiscal year ending on or about May 30, 2009. The restricted stock unit awards will be forfeited if the recipient ceases to be employed by the Company, competes with the business of the Company, or otherwise engages in activities detrimental to the Company's business before such date. The performance share awards and restricted stock units settle in shares of the Company's common stock on a one-for-one basis.

NOTE M - LITIGATION

Diomed v. AngioDynamics and

VNUS Medical Technologies v. Diomed, Vascular Solutions, and AngioDynamics

On January 6, 2004, Diomed, Inc. ("Diomed") filed an action against the Company entitled Diomed, Inc. v. AngioDynamics, Inc., civil action no. 04 10019 RGS in the U.S. District Court for the District of Massachusetts. Diomed's complaint alleges that the Company infringed on Diomed's U.S. patent no. 6,398,777 by selling a kit for the treatment of varicose veins (now called the "VenaCure Procedure Kit") and two diode laser systems: the Precision 980 Laser and the Precision 810 Laser, and by conducting a training program for physicians in the use of our VenaCure Procedure Kit. The complaint alleges the Company's actions have caused, and continue to cause, Diomed to suffer substantial damages. The complaint seeks to prohibit the Company from continuing to market and sell these products, as well as conducting a training program, and asks for compensatory and treble money damages, reasonable attorneys' fees, costs and pre-judgment interest. The Company believes that the Company's product does not infringe the Diomed patent.

On April 12, 2005, the Court issued a Memorandum and Order on Claims Construction, commonly known as a Markman ruling, in which the Court rejected Diomed's interpretation of certain claim limitations. Instead, the Court agreed with the Company on certain claim limitations and, as a result, effectively added additional weight to the Company's position that the proper use of its product does not infringe Diomed's patent.

In December 2005, the Company filed a motion for summary judgment of non-infringement in this action. Diomed, Inc. has also moved for summary judgment.

On January 3, 2006, the Company filed a declaratory judgment action in the U.S. Federal District court for the District of Delaware entitled AngioDynamics, Inc. v. Diomed Holdings, Inc., civ. action no. 06 002 (GMS) seeking a declaration by the court that the claims of Diomed's recently issued U.S. patent no. 6,981,971, entitled Medical Laser Device, are invalid, unenforceable and not infringed by the manufacture or sale of any of the Company's products, systems or processes, and that Diomed be stopped from asserting any of these claims against the Company. On January 17, 2006, the Company filed an Amended Complaint for Declaratory Judgment seeking a judgment declaring that the claims of a second Diomed patent, U.S. patent no. 6,986,766

Table of Contents

AngioDynamics, Inc. and Subsidiary

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

February 25, 2006 and February 26, 2005

(unaudited)

NOTE M - LITIGATION (continued)

entitled Method of Endovenous Laser treatment, are invalid, unenforceable and not infringed by the manufacture or sale of any of the Company's products, systems or processes, and that Diomed also be stopped from asserting any of these claims against the Company. On January 31, 2006, Diomed filed a motion to dismiss alleging that this declaratory judgment action should be dismissed as purportedly having no actual case or controversy between the Company and Diomed and stating that Diomed believed there was no imminent threat of litigation by Diomed against the Company. At this time, the Company cannot predict how the court will rule on this motion. If the motion is granted, this case will be dismissed, and Diomed will be able to file a patent infringement action against the Company at a later date. If the motion is denied, the case will proceed in the normal course.

On October 4, 2005, VNUS Medical Technologies, Inc. (VNUS) filed an action against the Company, and others (collectively, the Defendants) entitled VNUS Medical Technologies, Inc. v. Diomed Holdings, Inc., Diomed Inc., AngioDynamics, Inc., and Vascular Solutions, Inc., case no. C05-02972 MMC, filed in the U.S. District Court for the Northern District of California. The complaint alleges that the Defendants infringed on VNUS U.S. patent nos. 6,258,084, 6,638,273, 6,752,803, and 6,769,433 by making, using, selling, offering to sell and/or instructing users how to use Diomed's EVLT products, AngioDynamics VenaCure products, and Vascular Solutions Vari-Lase products. The complaint alleges the Defendants' actions have caused, and continue to cause, VNUS to suffer substantial damages. The complaint seeks to prohibit the Defendants from continuing to market and sell these products and asks for compensatory and treble money damages, reasonable attorneys' fees, costs and pre-judgment and post-judgment interest. The Company believes that its product does not infringe the VNUS patents and has filed an answer to the complaint, including a counterclaim for relief and a demand for jury trial.

The Company purchases the lasers and laser fibers for its laser systems from biolitec Inc. (biolitec) under a supply and distribution agreement. In response to the Company's request to biolitec that it assume the defense of the VNUS action, biolitec advised the Company that the claims asserted in the VNUS action were not covered by the indemnification provisions in the supply and distribution agreement. biolitec further advised the Company that, based on the refinement of the claims in the Diomed action, such claims were also not within biolitec's indemnification obligations under the agreement. The Company advised biolitec that it disagreed with biolitec's position and that the Company expected biolitec to continue to honor its indemnification obligations to the Company under the agreement. The Company is engaged in discussions with biolitec to resolve this disagreement. Pending the outcome of these ongoing discussions, biolitec has agreed to continue to provide, at its cost and expense, the Company's defense in the Diomed action, but contrary to what the Company believed its understanding with biolitec to be, has not agreed to pay the costs of defense of the VNUS action as they are incurred. Consequently, the Company is currently paying those costs. Should it ultimately be determined that the claims asserted in these actions are not within biolitec's indemnification obligations under the supply and distribution agreement, the Company will be unable to recover the costs incurred in defending the VNUS action, and will be

Table of Contents

AngioDynamics, Inc. and Subsidiary

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

February 25, 2006 and February 26, 2005

(unaudited)

NOTE M - LITIGATION (continued)

responsible for paying any settlements or judgments in these actions. There is a reasonable possibility of an outcome unfavorable to the Company in the Diomed action, with a range of potential loss at between \$674,000 and \$5.6 million dollars.

Chapa, San Juanita v. Spohn Hospital Shoreline

The Company has been named as a defendant in an action entitled Chapa, San Juanita, et. al v. Spohn Hospital Shoreline, et al, file no. 03-60961-00-0-1, filed in the District Court of Nueces County, Texas, on July 22, 2003, and re-filed in November 2004. The complaint alleges that the Company and its co-defendant, Medcomp, designed, manufactured, sold, distributed and marketed a defective catheter that was used in the treatment of, and caused the death of, a hemodialysis patient, as well as committing other negligent acts. The complaint seeks compensatory and other monetary damages in unspecified amounts. The Company has tendered the defense of the Chapa action to Medcomp, and Medcomp has accepted defense of the action. Based upon the Company's prior experience with Medcomp, it expects Medcomp to honor its indemnification obligation to the Company if it is unsuccessful in defending this action.

The Company is party to other legal actions that arise in the ordinary course of business. The Company believes that any liability resulting from any currently pending litigation will not, individually or in the aggregate, have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

Table of Contents

Item 2. **Management's Discussion and Analysis of Financial Condition and Results of Operations**

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this Quarterly Report on Form 10-Q.

Forward-Looking Statements

This Quarterly Report on Form 10-Q, including the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations", contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are intended to be covered by the safe harbors created thereby. In some cases, forward-looking statements may be identified by terminology such as "may", "will", "should", "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates", "predicts", "potential", "continue" or variations of such terms or similar expressions. Forward-looking statements relate to future events or AngioDynamics' future financial performance and involve known and unknown risks, uncertainties and other factors that may cause AngioDynamics or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors include, among other things, our ability to develop new products and enhance existing products, our ability to protect our intellectual property, pending and potential intellectual property infringement claims by third parties, our dependence on single source suppliers, our relationships with interventional physicians, the difficulty in predicting our sales and planning our manufacturing requirements, the performing by cardiologists of more interventional procedures, possible undetected defects in our products, pending and potential product liability claims by customers or patients, the volatility of our operating results, the effect on our operations of healthcare reform measures, potential declines in reimbursements by government or other third-party payors for procedures using our products, failure to obtain regulatory approvals for our products, a disaster or other disruption at our manufacturing facility or the facilities of our suppliers, and our likely need for additional financing to fund any significant acquisitions. We discuss certain of these matters more fully in other of our filings with the SEC, including our Annual Report on Form 10-K for our 2005 fiscal year, which was filed with the SEC on August 26, 2005. This Quarterly Report should be read in conjunction with that Annual Report on Form 10-K, and all our other filings, including Current Reports on Form 8-K, made with the SEC through the date of this report. We urge you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this Quarterly Report. As a result of these matters, including changes in facts or other factors, the actual circumstances relating to the subject matter of any forward-looking statement in this Quarterly Report may differ materially from the anticipated results expressed or implied in that forward-looking statement. The forward-looking statements included in this Quarterly Report are made only as of the date of this report and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances.

Overview

AngioDynamics is a provider of innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease, or PVD. We design, develop, manufacture and market a broad line of therapeutic and diagnostic devices that enable interventional physicians (interventional radiologists, vascular surgeons and others) to treat PVD and other non-coronary diseases. We believe that we are the only company whose primary focus is to offer a comprehensive product line for the interventional treatment of these diseases.

Table of Contents

We sell our broad line of quality devices in the United States through a direct sales force which, as of February 25, 2006, was comprised of 47 sales persons, seven regional managers and a vice president of sales. In an effort to generate increased sales, we intend to expand our domestic sales force to 70 direct sales representatives within the next three years. Outside the United States, we sell our products indirectly through a network of distributors in 34 markets. Historically, no more than 5% of our net sales have been in non-U.S. markets.

Our growth depends in large part on the continuous introduction of new and innovative products, together with ongoing enhancements to our existing products, through internal product development, technology licensing, and strategic alliances. In this regard, our strategic plan calls for an annual investment of 8% of sales for research and development activities.

In addition, we are seeking to grow through selective acquisitions of complementary businesses and technologies. Our cash resources are limited and, except to the extent we can use our equity securities as acquisition capital, which is also limited, until November 2006, due to restrictions related to our spin-off from E-Z-EM, we will require additional equity or debt financing to fund any significant acquisitions. We cannot assure you that we will be able to successfully identify or consummate any such acquisitions or that any required financing will be available on terms satisfactory to us or at all.

Consistent with our growth strategy, in October 2005, we entered into a Supply and Distribution Rights Agreement with Bioniche Pharma Group Limited to be the exclusive distributor in our field of Sotradecol™, a sclerosing drug that was recently approved by the FDA. We believe that Sotradecol will become an important treatment method for small, uncomplicated varicose veins. We believe that the addition of Sotradecol to our existing venous product portfolio gives us an opportunity to be a market leader in treatment methods for all varicose vein conditions.

Our ability to further increase our profitability will depend in large part on continuing to improve our gross profit margin. As discussed below, our gross profit margin has improved significantly in recent periods, primarily due to increased sales of higher margin products. We expect continued steady growth of our gross profit margin, as we expand our efforts to increase sales of such higher margin products as our Morpheus CT PICC and EvenMore catheter, and develop and introduce additional higher margin products. We also plan to take advantage of our expanded production facility to manufacture more of the products we sell, which we anticipate will further improve our margins. However, we cannot assure you that our efforts will result in continued improvement in our gross margins and profitability. We expect that revenue growth and gross margin improvements will continue to be offset somewhat by increases in selling expenses from the addition of direct sales personnel, as discussed above, and from additional administrative expenses necessary to support our growing enterprise.

Our fiscal nine months ended February 25, 2006 and February 26, 2005 both represent thirty-nine weeks. The thirty-nine weeks ended February 25, 2006 are referred to as the fiscal 2006 period and the thirty-nine weeks ended February 26, 2005 are referred to as the fiscal 2005 period. Our fiscal quarters ended February 25, 2006 and February 26, 2005 both represent thirteen weeks. The thirteen weeks ended February 25, 2006 are referred to as the 2006 quarter and the thirteen weeks ended February 26, 2005 are referred to as the 2005 quarter.

For the fiscal 2006 period, we reported net income of \$4.8 million, or approximately \$0.39 and \$0.37 per common share on a basic and diluted basis, respectively, on revenues of \$54.9 million. For the fiscal 2005 period, we reported net income of \$2.9 million, or approximately \$0.25 and \$0.24 per common

Table of Contents

share on a basic and diluted basis, respectively, on revenues of \$43.0 million. Gross profit margin improved to 58.2% for the fiscal 2006 period from 55.0% for the fiscal 2005 period. Cash flow from operations was \$4.7 million, an increase of \$1.7 million from the fiscal 2005 period.

Results of Operations**Thirteen weeks ended February 25, 2006 and February 26, 2005**

The following table sets forth certain operational data as a percentage of sales for the thirteen weeks ended February 25, 2006 and February 26, 2005.

	Thirteen weeks ended	
	February 25, 2006	February 26, 2005
Net Sales	100.0%	100.0%
Gross profit	58.4%	55.4%
Selling and marketing expenses	26.8%	26.8%
General and administrative expenses	9.7%	8.1%
Research and development expenses	7.3%	6.6%
Operating profit	14.6%	13.9%
Other income	1.1%	(1.6)%
Net income	9.5%	7.0%

Net Sales. Net sales for the 2006 quarter increased by 28.1%, or \$4.3 million, to \$19.8 million, compared with the 2005 quarter. The increase in sales was primarily due to the continued growth from new products released in, or subsequent to, the 2005 quarter as well as the continuing market share gains of our existing product lines. Faster growing products included our image-guided vascular access line, for which sales increased 58.5% or \$1.2 million, due primarily to the continued growth of our Morpheus CT PICC; dialysis products, for which sales increased by 18.9%, or \$801,000; venous products, for which sales increased by 80.5%, or \$1.4 million; and angiographic products, for which sales increased 15.9%, or \$730,000. All of the increase in our sales was due to increased unit sales.

Gross Profit. For the 2006 quarter, our gross profit as a percentage of sales increased to 58.4% from 55.4% for the 2005 quarter. The increase in gross profit margin was primarily the result of a favorable product mix from increased sales of higher margin products, such as our EvenMore catheter, the VenaCure procedure kit, and the Morpheus CT PICC, and production efficiencies resulting from continuous efforts to streamline the manufacturing process.

Selling and marketing expenses. Selling and marketing expenses were 26.8% of net sales for the 2006 and 2005 quarters. For the 2006 quarter, these expenses increased 27.7%, or \$1.1 million, compared with the 2005 quarter. Selling expenses increased 33.7%, or \$997,000, due to personnel expenses related to the increased number of territories and commissions on higher sales. Marketing expenses increased 12.7%, or \$151,000, due to professional society membership fees, product promotions, and market research fees.

General and administrative expenses. General and administrative expenses were 9.7% of net sales for the 2006 quarter, compared with 8.1% for the 2005 quarter. For the 2006 quarter, these expenses increased 54.3%, or \$675,000, partially due to increased legal and consulting fees, accounting fees related to quarterly reviews, income tax return filings, and internal controls review required by Section 404 of the Sarbanes-Oxley Act, as well as amortization of a recently implemented business software platform. Non-recurring consulting fees incurred in conjunction with our initial efforts to comply with Section 404 of the Sarbanes-Oxley Act comprised \$189,000 of this increase, or 1.0% of net sales for the 2006 quarter.

Table of Contents

Research and development expenses. Research and development (R&D) expenses were 7.3% of net sales for the 2006 quarter, compared to 6.6% for the 2005 quarter. R&D expenses increased by 40.9%, or \$420,000, due to expenses associated with ongoing projects.

Other Income (Expenses). Other income increased \$469,000 to \$224,000 for the 2006 quarter, partially due to an increase in interest income of \$142,000. Both an increase in our investment portfolio and higher yields contributed to this increase. The 2005 quarter included an impairment charge of \$300,000 related to our investment in Surgica Corporation.

Income Taxes. Our effective tax rate for the 2006 quarter was 39.6% compared to 43.0% for the 2005 quarter. The decrease is attributable to a non-deductible capital loss incurred during the 2005 quarter, offset by additional income taxes incurred in the 2006 quarter under our tax sharing arrangement with our former parent company, E-Z-EM, Inc. (E-Z-EM), in connection with its filing of the consolidated fiscal 2005 Federal income tax return, which included our taxable income prior to our spin-off (the Spin-off) by E-Z-EM.

Net Income. For the 2006 quarter, we reported net income of \$1.9 million, an increase of 73.3%, or \$795,000, over net income of \$1.1 million for the 2005 quarter. The increase in net income was attributable primarily to increased sales, higher gross profit margin and increased investment income, partially offset by higher operating expenses.

Thirty-nine weeks ended February 25, 2006 and February 26, 2005

The following table sets forth certain operational data as a percentage of sales for the thirty-nine weeks ended February 25, 2006 and February 26, 2005.

	Thirty-nine weeks ended	
	February 25,	February 26,
	2006	2005
Net Sales	100.0%	100.0%
Gross profit	58.2%	55.0%
Selling and marketing expenses	27.5%	26.5%
General and administrative expenses	9.4%	8.8%
Research and development expenses	8.2%	7.6%
Operating profit	13.1%	12.1%
Other income (expense)	1.1%	(0.5)%
Net income	8.8%	6.7%

Net Sales. Net sales for the fiscal 2006 period increased by 27.7%, or \$11.9 million, to \$54.9 million, compared to the fiscal 2005 period. The increase in sales was primarily due to the continued growth from new products released in, or subsequent to, the fiscal 2005 period as well as the continuing market share gains of our existing product lines. Faster growing products included our image-guided vascular access line, for which sales increased 93.5% or \$4.2 million, due primarily to the continued growth of our Morpheus CT PICC; dialysis products, for which sales increased by 19.8%, or \$2.4 million; venous products, for which sales increased by 55.0%, or \$2.8 million; and angiographic products, for which sales increased 14.8%, or \$1.9 million. All of the increase in our sales was due to increased unit sales.

Gross Profit. For the fiscal 2006 period, gross profit as a percentage of sales increased to 58.2% from 55.0% for the fiscal 2005 period. The increase in gross margin percentage was due to a favorable product mix resulting from increased sales of higher margin products, such as our EvenMore catheter, the VenaCure procedure kit, and the Morpheus CT PICC, and production efficiencies resulting from continuous efforts to streamline the manufacturing process.

Table of Contents

Selling and marketing expenses. Selling and marketing expenses were 27.5% of net sales for the fiscal 2006 period, compared to 26.5% for the fiscal 2005 period. For the fiscal 2006 period, selling and marketing expenses increased 32.0%, or \$3.6 million, compared to the fiscal 2005 period. Selling expenses increased 38.8%, or \$3.1 million, due to personnel expenses related to the increased number of territories and commissions on higher sales, as well as product promotions and samples. Marketing expenses increased 15.4%, or \$507,000, due to increased personnel expenses, product promotions, professional society membership fees, and convention expenses.

General and administrative expenses. General and administrative expenses were 9.4% of net sales for the fiscal 2006 period, compared to 8.8% for the fiscal 2005 period. For the fiscal 2006 period these expenses increased 38.0%, or \$1.4 million, partially due to increased legal and consulting fees, accounting fees for audit and quarterly reviews, income tax return filings, and internal controls review required by Section 404 of the Sarbanes-Oxley Act, as well as computer supplies and amortization expense related to a recently implemented business software platform. Non-recurring consulting fees incurred in conjunction with our initial efforts to comply with Section 404 of the Sarbanes-Oxley Act comprised \$239,000 of this increase, or 0.4% of net sales for the fiscal 2006 period.

Research and development expenses. Research and development (R&D) expenses were 8.2% of net sales for the fiscal 2006 period, compared to 7.6% for the fiscal 2005 period. R&D expenses increased by 37.7%, or \$1.2 million, due to expenses associated with ongoing projects.

Other Income (Expenses). Other income increased \$802,000 to \$595,000 for the fiscal 2006 period, due to an increase in interest income of \$359,000. Both an increase in our investment portfolio and higher yields contributed to this increase. Other income for the fiscal 2006 period also included an increase in realized gains on the sale of marketable securities of \$133,000. The fiscal 2005 period included an impairment charge of \$300,000 related to our investment in Surgica Corporation.

Income Taxes. Our effective tax rate for the fiscal 2006 period was 38.1% compared to 42.4% for the fiscal 2005 period. The decrease is attributable to research and development credits recorded in the fiscal 2006 period, plus a decrease in state taxes compared to the fiscal 2005 period, which included a catch-up provision for states in which we had recently attained a taxable presence. Additionally, the fiscal 2005 period included a non-deductible capital loss. These decreases were offset by additional income taxes incurred in the fiscal 2006 period under our tax sharing arrangement with E-Z-EM, in connection with E-Z-EM's filing of the consolidated fiscal 2005 Federal income tax return, which included our taxable income prior to the Spin-off.

Net Income. For the fiscal 2006 period, we reported net income of \$4.8 million, an increase of 67.5%, or \$1.9 million, over the fiscal 2005 period. The increase in net income was attributable primarily to increased sales and higher gross margin, offset somewhat by increased operating expenses, as discussed above.

Liquidity and Capital Resources

For the fiscal 2006 period, we generated cash flow from operations of \$4.7 million on net income of \$4.8 million. A tax benefit on the exercise of stock options of \$1.3 million, depreciation and amortization expense of \$756,000, and increases in accounts payable were partially offset by increases in inventory and accounts receivable.

For the fiscal 2006 period, our investing activities used net cash of \$7.7 million, due to three reasons. We had a net investment of \$2.9 million of excess

Table of Contents

cash and cash generated from operations into U.S. Government obligations and corporate securities. Installment payments for distribution rights under an exclusive supply and distribution agreement, together with costs to execute the agreement, totaled \$2.4 million. Additionally, we made equipment purchases and building improvements totaling \$2.4 million, of which approximately \$1.5 million related to our implementation and conversion to a new enterprise resource planning system.

Financing activities provided net cash of \$1.9 million for the fiscal 2006 period, due to proceeds of \$2.0 million received from the exercise of stock options and purchases under our employee stock purchase plan. Principal payments on our long-term debt totaled \$120,000.

There have been no material changes with respect to our contractual obligations and their effect on liquidity and cash flows previously disclosed in our Annual Report on Form 10-K for our fiscal year ended May 28, 2005.

For the fiscal 2006 period, we funded capital expenditures and our working capital requirements (exclusive of the aforementioned installment payments of \$2.4 million under a supply and distribution agreement) with cash from operations. Our current policy is to fund operations and capital requirements without incurring significant debt. In fiscal 2003, we financed our facility expansion with long-term industrial revenue bonds. As of February 25, 2006, and May 28, 2005, debt (current maturities of long-term debt and long-term debt) was \$3.0 million and \$3.1 million, respectively. On November 23, 2005, we replaced our \$3.0 million bank line of credit with a \$7.5 million line of credit facility with KeyBank National Association, with a maturity date of November 30, 2006. No amounts were outstanding under the line of credit as of February 25, 2006.

As of February 25, 2006, \$28.9 million, or 41.2%, of our assets consisted of cash and cash equivalents and marketable securities. Marketable securities are comprised of corporate bonds and U.S. government issued or guaranteed securities. The current ratio was 5.6 to 1, with working capital of \$46.0 million, as of February 25, 2006, compared to a current ratio of 6.5 to 1, with working capital of \$42.1 million, as of May 28, 2005.

We are also restricted in our ability to obtain equity financing due to the distribution by E-Z-EM of our stock to its stockholders, which was completed on October 30, 2004. We are limited in the amount of equity securities or convertible debt we can issue until November 2006 in order to preserve the tax-free treatment of the distribution and avoid tax liabilities to E-Z-EM and its stockholders and corresponding liabilities to us. Specifically, we are limited to issuing no more than approximately 5.5 million shares of our common stock in capital raising transactions over this period.

We believe that our current cash and investment balances, which include the net proceeds from our initial public offering, together with cash generated from operations and our existing line of credit, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If, as discussed above, we seek to make significant acquisitions of other businesses or technologies, we will, in all likelihood, require additional financing. We cannot assure you that such financing will be available on commercially reasonable terms, if at all.

Critical Accounting Policies and Use of Estimates

Our significant accounting policies are summarized in Note A to our consolidated financial statements included in our Annual Report on Form 10-K for our 2005 fiscal year. While all these significant accounting policies affect the reporting of our financial condition and results of operations, we view certain of these

Table of Contents

policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require us to use a greater degree of judgment and/or estimates. Actual results may differ from those estimates. The accounting policies identified as critical are as follows:

Revenue Recognition

We recognize revenue in accordance with generally accepted accounting principles as outlined in the SEC's Staff Accounting Bulletin No. 104, Revenue Recognition, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence that an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered. Decisions relative to criterion (iii) regarding collectability are based upon our judgments, as discussed under Accounts Receivable below, and should conditions change in the future and cause us to determine this criterion is not met, our results of operations may be affected. We recognize revenue as products are shipped, based on F.O.B. shipping point terms when title passes to customers. We negotiate shipping and credit terms on a customer-by-customer basis and products are shipped at an agreed upon price. All product returns must be pre-approved by us and, if approved, customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least 12 months remaining prior to its expiration date.

Accounts Receivable

Accounts receivable, principally trade, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for doubtful accounts. We perform ongoing credit evaluations of our customers and adjust credit limits based upon payment history and the customer's current credit worthiness, as determined by a review of their current credit information. We continuously monitor aging reports, collections and payments from customers, and maintain a provision for estimated credit losses based upon our historical experience and any specific customer collection issues that we identify. While such credit losses have historically been within our expectations and the provisions established, we cannot guarantee that the same credit loss rates will be experienced in the future. We write off accounts receivable when they become uncollectible.

Income Taxes

In preparing our financial statements, we calculate income tax expense for each jurisdiction in which we operate. This involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. We periodically evaluate deferred tax assets, capital loss carryforwards and tax credit carryforwards to determine their recoverability based primarily on our ability to generate future taxable income and capital gains. Where their recovery is not likely, we estimate a valuation allowance and record a corresponding additional tax expense in our statement of income. If actual results differ from our estimates due to changes in assumptions, the provision for income taxes could be materially affected. As of February 25, 2006, our valuation allowance and net deferred tax asset were approximately \$628,000 and \$1.3 million, respectively. We had a tax allocation and indemnification agreement with E-Z-EM with whom we filed consolidated Federal tax returns for periods through October 30, 2004. Under this agreement, we paid Federal income tax based on the amount of taxable income we generated and were credited for Federal tax benefits we generated that could be used by us or other members of the consolidated group. This agreement did not cover tax liabilities arising from state, local and other taxing authorities to whom we report separately.

Table of Contents

Inventories

We value inventories at the lower of cost (on the first-in, first-out method) or market. On a quarterly basis, we review inventory quantities on hand and analyze the provision for excess and obsolete inventory based primarily on product expiration dating and our estimated sales forecast, which is based on sales history and anticipated future demand. Our estimates of future product demand may not be accurate and we may understate or overstate the provision required for excess and obsolete inventory. Accordingly, any significant unanticipated changes in demand could have a significant impact on the value of our inventory and results of operations. As of February 25, 2006 and May 28, 2005, our reserve for excess and obsolete inventory was \$1.2 million and \$779,000, respectively.

Property, Plant and Equipment

We state property, plant and equipment at cost, less accumulated depreciation, and depreciate these assets principally using the straight-line method over their estimated useful lives. We determine this based on our estimates of the period over which the assets will generate revenue. We evaluate these assets for impairment annually or as changes in circumstances or the occurrence of events suggest the remaining value is not recoverable. Any change in condition that would cause us to change our estimate of the useful lives of a group or class of assets may significantly affect depreciation expense on a prospective basis.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk from changes in interest rates on investments and financing, which could impact our results of operations and financial position. Although we have entered into an interest rate swap with a bank to limit our exposure to interest rate change market risk on our variable interest rate financing, we do not currently engage in any other hedging or market risk management tools.

Our excess cash is primarily invested in highly liquid, short-term investment grade securities of less than one year. These investments are not held for speculative or trading purposes. Changes in interest rates may affect the investment income we earn on cash, cash equivalents and debt securities and therefore affect our cash flows and results of operations. As of February 25, 2006, we were exposed to interest rate change market risk with respect to our investments in callable U.S. Government agency obligations in the amount of \$995,000. The interest rate on the callable bonds is subject to the call option being exercised by the debtor. For the thirty-nine weeks ended February 25, 2006, the weighted average after-tax interest rate on the callable bonds approximated 1.8%. Each 100 basis point (or 1%) fluctuation in interest rates will increase or decrease interest income on the government bonds by approximately \$10,000 on an annual basis.

As of February 25, 2006, we maintained variable interest rate financing of \$2,980,000 in connection with our facility expansion. We have limited our exposure to interest rate risk by entering into an interest rate swap agreement with a bank under which we agreed to pay the bank a fixed annual interest rate of 4.45%, and the bank assumed our variable interest payment obligations under the financing.

On November 23, 2005, we entered into a \$7,500,000 working capital line of credit with a bank. The initial advance under the line of credit will bear interest at the rate of LIBOR plus 175 basis points (the LIBOR rate .) Thereafter, the interest rate will be adjusted monthly at our election, to either the then-current LIBOR rate or the bank's prime rate. We will thus be exposed to interest rate risk with respect to this credit facility to the extent that interest rates rise when there are amounts outstanding under the facility.

Table of Contents

Item 4. **Controls and Procedures**

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report have been designed and are functioning effectively to provide reasonable assurance that the information required to be disclosed by us (including our consolidated subsidiary) in reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

No change in our internal control over financial reporting occurred during the quarter ended February 25, 2006 that has materially affected or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

AngioDynamics, Inc. and Subsidiary

Part II: Other Information

Item 1. **Legal Proceedings**

Certain legal proceedings in which we are involved are discussed in Part I, Item 3 of our annual report on Form 10-K for the fiscal year ended May 28, 2005.

We are a defendant in two actions in which the plaintiffs allege that the manufacture, use and sale of our VenaCure laser system infringe on patents owned by them. These actions, which we have previously reported in our filings with the SEC, are entitled Diomed, Inc. v. AngioDynamics, Inc., civil action no. 04 10019 RGS in the U.S. District Court for the District of Massachusetts, and VNUS Medical Technologies, Inc. v. Diomed Holdings, Inc., Diomed Inc., AngioDynamics, Inc., and Vascular Solutions, Inc., case no. C05-02972 MMC, filed in the U.S. District Court for the Northern District of California.

We purchase our lasers and laser fibers for our laser systems from biolitec, Inc. (biolitec) under a supply and distribution agreement. In response to our request to biolitec that it assume the defense of the VNUS action, biolitec advised us that the claims asserted in the VNUS action were not covered by the indemnification provisions in the supply and distribution agreement. biolitec further advised us that, based on the refinement of the claims in the Diomed action, such claims were also not within biolitec s indemnification obligations under the agreement. We advised biolitec that we disagreed with its position and that we expected it to continue to honor its indemnification obligations to us under our agreement. We are engaged in discussions with biolitec to resolve this disagreement. Pending the outcome of these ongoing discussions, biolitec has agreed to continue to provide, at its cost and expense, our defense in the Diomed action but, contrary to what we believed our understanding with biolitec to be, has not agreed to pay the costs of defense of the VNUS action as they are incurred. Consequently, we are currently paying these costs. Should it ultimately be determined that the claims asserted in these actions are not within biolitec s indemnification obligations under the supply and distribution agreement, we will be unable to recover the costs incurred in defending the VNUS action and will be responsible for paying any settlements or judgments in these actions. There is a reasonable possibility of an outcome unfavorable to us in the Diomed action, with a range of potential loss of between \$674,000 and \$5.6 million dollars.

In December 2005, we filed a motion for summary judgment of non-infringement in the above-described Diomed action in the U.S. District Court for the District of Massachusetts. Diomed has also moved for summary judgment in this action.

On January 3, 2006, we filed a declaratory judgment action in the U.S. Federal District court for the District of Delaware entitled AngioDynamics, Inc. v. Diomed Holdings, Inc., civ. action no. 06 002 (GMS) seeking a declaration by the court that the claims of Diomed s recently issued U.S. patent no. 6,981,971, entitled Medical Laser Device, are invalid, unenforceable and not infringed by the manufacture or sale of any of our products, systems or processes, and that Diomed be stopped from asserting any of these claims against us. On January 17, 2006, we filed an Amended Complaint for Declaratory Judgment seeking a judgment declaring that the claims of a second Diomed patent, U.S. patent no. 6,986,766 entitled Method of Endovenous Laser Treatment, are invalid, unenforceable and not infringed by the manufacture or sale of any of our products, systems or processes, and that Diomed also be stopped from asserting any of these claims against us. On January 31, 2006, Diomed filed a motion to dismiss alleging that this declaratory judgment action should be dismissed as purportedly having no

Table of Contents

actual case or controversy between us and Diomed and stating that Diomed believed there was no imminent threat of litigation by Diomed against us. At this time, we cannot predict how the court will rule on this motion. If the motion is granted, this case will be dismissed, and Diomed will be able to file a patent infringement action against us at a later date. If the motion is denied, the case will proceed in the normal course.

We are party to other legal actions that arise in the ordinary course of our business. We believe that any liability resulting from any currently pending litigation will not, individually or in the aggregate, have a material adverse effect on our business, financial position, or results of operations.

Item 1A. **Risk Factors**

Not applicable.

Item 2. **Unregistered Sales of Equity Securities and Use of Proceeds**

Our initial public offering on Form S-1 (reg. No. 333-113329) was declared effective on May 26, 2004.

The following table sets forth our uses of the net proceeds of the offering from the effective date of the offering to the last day of the fiscal quarter covered by this report:

Initial Public Offering
Use of proceeds
as of February 25, 2006
(\$ in thousands)

Description	Balance
Receipt of net proceeds of Initial Public Offering and underwriters over allotment option	\$ 22,941
Repayment of note payable to E-Z-EM, Inc.	(3,000)
Payment of expenses related to our initial public offering.	(1,505)
Payments under a licensing and distribution agreement.	(2,393)
Installment payments under a research and distribution agreement	(800)
Net proceeds as of February 25, 2006.	\$ 15,243

Item 3. **Defaults Upon Senior Securities**

None.

Item 4. **Submission Of Matters to a Vote of Security Holders**

None.

Item 5. **Other Information**

None.

Table of Contents

Item 6. **Exhibits**

No.	Description
10.1	Commitment Letter dated November 23, 2005, from KeyBank National Association. (a)
10.2	Promissory Note dated November 23, 2005, between AngioDynamics, Inc. and KeyBank National Association. (a)
10.3	Commercial Security Agreement dated November 23, 2005, between AngioDynamics, Inc. and KeyBank National Association. (a)
31.1	Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934*
31.2	Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934*
32.1	Certification of Chief Executive Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

* Previously filed.

(a) Incorporated by reference to the exhibit of the same number to the registrant's current report on Form 8-K filed on November 30, 2005.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ANGIODYNAMICS, Inc.

(Registrant)

Date April 11, 2006

/s/ Eamonn P. Hobbs
Eamonn P. Hobbs, President,
Chief Executive Officer

Date April 11, 2006

/s/ Joseph G. Gerardi
Joseph G. Gerardi, Vice President - Chief Financial Officer

(Principal Financial and Chief Accounting Officer)